All news

Agilent splits up to create two separate businesses

Agilent splits up to create two separate businesses

Agilent Technologies has officially separated its biopharma service offerings from its electric measurement group to create two separate companies, the life science portion of which is expected to bring in about $3.9B in FY2013.

Industry must ensure tech not used to make bioweapons says UN

EDITOR'S BLOG

BioPharma Tech Firms Can Help Prevent Bioweapon Production, Says UN

By Gareth Macdonald

Making germ warfare weapons is banned under the Biological Weapons Convention (BWC) and there is no evidence signatories or even countries led by any of the World’s crackpot dictators/freedom fighters* are producing them.

New Melanoma Vaccine Tech Enters Ph I Trial

Harvard’s New Melanoma Vaccine Tech Enters Ph I Trial

By Zachary Brennan

A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.

Horizon Licenses ZFN Tech from Sigma-Aldrich

Horizon Licenses ZFN Tech from Sigma-Aldrich

By Dan Stanton

Horizon Discovery has licensed a zinc finger nuclease (ZFN) technology from Sigma-Aldrich and says the combination with its own platform will be “a big step forward in gene editing.”

CST Unveils HER3 Rabbit mAb for Researchers

CST Unveils HER3 Rabbit mAb for Researchers

By Zachary Brennan

Cell Signaling Technology launched a new HER3 rabbit monoclonal antibody (mAb) for researchers studying HER2-mediated breast, lung and ovarian tumors. 

Single-Use Growth Offsets Pall's Muted Results

Single-Use Growth Offsets Pall's Muted Results

By Dan Stanton

Pall Corporation says it will continue to invest in single-use systems after reporting substantially higher growth in sales compared to stainless steel systems for the 2013 FY.

FDA Grants Novartis Biologic Breakthrough Status

FDA Grants Novartis Biologic Breakthrough Status

By Dan Stanton

A third Novartis biopharmaceutical has received breakthrough designation status from the FDA allowing ‘fast-track’ development and review without compromising safety, the company says.

More Manufacturing Issues Lead to Alexion Recall

More Manufacturing Issues Lead to Alexion Recall

By Dan Stanton

Alexion Pharma International has recalled a single lot of its monoclonal antibody (MAb) orphan drug Soliris due to the presence of visible particles in a limited number of vials.

Follow us

Webinars